COYA

Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index

Retrieved on: 
tisdag, maj 28, 2024
Neurology, Biotechnology, Pharmaceutical, Finance, General Health, Health, Infectious Diseases, Professional Services, Risk, COYA, Therapy, ETF, ALS, Research, Frontotemporal dementia

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that MSCI has selected the Company’s shares for inclusion in its MSCI USA Micro Cap Index at the market close of May 31, 2024.

Key Points: 
  • Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that MSCI has selected the Company’s shares for inclusion in its MSCI USA Micro Cap Index at the market close of May 31, 2024.
  • The MSCI USA Micro Cap Index is designed to measure the performance of the micro cap segment of the U.S. equity market and is comprised of over 1,100 constituents with an average market cap of $122 million at April 30, 2024.
  • “Being selected by MSCI is a testament to the strategic focus and execution of the Coya team in creating sustainable shareholder value,” commented Howard Berman, Ph.D., Chief Executive Officer of Coya.
  • MSCI creates industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process.

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease

Retrieved on: 
onsdag, maj 22, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, ADAS-Cog, Patient, Mini–Mental State Examination, COYA, Therapy, LD, Safety, Blood, CMO, Biomarker, Cerebrospinal fluid, Dementia, Coya, DRS, Houston Methodist Hospital, Melinda French Gates, Pharmaceutical industry

Stanley Appel and Alireza Faridar at Houston Methodist Hospital and is funded by the Gates Foundation and the Alzheimer’s Association.

Key Points: 
  • Stanley Appel and Alireza Faridar at Houston Methodist Hospital and is funded by the Gates Foundation and the Alzheimer’s Association.
  • This controlled Phase 2 study will evaluate the safety, tolerability, and biological activity of LD IL-2 in patients with AD compared to placebo at pre-specified intervals.
  • Fred Grossman D.O., President and CMO of Coya Therapeutics, stated, “This is an important study that will help advance our expanding pipeline in dementia.
  • Overall, administration of LD IL-2 appeared to be well tolerated in the eight patients in the open-label, proof-of concept study.

Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)

Retrieved on: 
måndag, maj 20, 2024
Research, Neurology, Clinical Trials, Philanthropy, Biotechnology, Health, Pharmaceutical, Foundation, Science, Fillit, Security (finance), Patient, Regulation D, The Act, Dementia, COYA, Therapy, Disease, Sale, ALS, Central nervous system, Entrepreneurship, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the Alzheimer’s Drug Discovery Foundation (“ADDF”) has purchased 603,136 shares of the Company’s common stock at a purchase price of $8.29 per share for an aggregate investment of $5 million.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the Alzheimer’s Drug Discovery Foundation (“ADDF”) has purchased 603,136 shares of the Company’s common stock at a purchase price of $8.29 per share for an aggregate investment of $5 million.
  • The ADDF’s mission is to rapidly accelerate the development of drugs to prevent, treat, and cure Alzheimer’s disease (AD) and related dementias, including FTD.
  • Coya’s lead therapeutic candidate, COYA 302, is being evaluated in multiple neurodegenerative diseases, including FTD, and the Company intends for this equity investment to help fund the development of COYA 302 in a planned Phase 2 trial in FTD.
  • “Inflammation has emerged as a promising novel pathway for chronic neurological diseases like FTD.

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 9, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, FDA, COYA, University, FTD, Society, Cancer, Viral, Laboratory, Survival, Coya, Conference, GM-CSF, Nebraska Medicine, IND, Granulocyte-macrophage colony-stimulating factor, Pharmacology, Frontotemporal dementia, Patient, Caregiver, Medulla oblongata, Serum, ALS, Diagnosis, PD, Therapy, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024.
  • Additionally, clinical data from the previously completed investigator-initiated trial in patients with ALS is also anticipated in the second quarter.
  • 2 investigator-initiated trial involving COYA 301, or low-dose IL-2 alone, is expected in the summer of 2024.
  • As of March 31, 2024, Coya had cash and cash equivalents of $36.0 million.

Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Retrieved on: 
fredag, april 26, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Doctor of Philosophy, COYA, Reactive oxygen species, Oxidative stress, Houston Methodist Hospital, HMH, Survival, ROS, Death, Disease, Patient, Medulla oblongata, ALS, Diagnosis, Associate, Therapy, Pharmaceutical industry

The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and survival in ALS patients from a longitudinal patient registry cohort.

Key Points: 
  • The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and survival in ALS patients from a longitudinal patient registry cohort.
  • Reactive oxygen species (ROS) are generated mainly as byproducts of mitochondrial respiration and are tightly controlled by multiple anti-oxidant mechanisms.
  • In neurodegenerative diseases, such as ALS, when the antioxidant system is overwhelmed by overproduction of ROS, oxidative stress occurs.
  • 4-HNE, an abundant and reactive oxygen species, is thought to exert neuronal toxicity ultimately through formation of toxic protein aggregates, as seen in ALS patients.

Coya Therapeutics to Participate in the Mizuho Neuroscience Summit

Retrieved on: 
måndag, april 22, 2024
Health, Neurology, Other Health, General Health, Pharmaceutical, Biotechnology, DRS, COYA, Therapy, Boston Harbor Hotel

More information on the Mizuho Neuroscience Summit can be found at the link below: https://www.mizuhogroup.com/americas/events/2024/mizuho-neuroscience-sum...

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer and Chairman of the Board Howard Berman, Ph.D., and Chief Business Development Officer Arun Swaminathan, Ph.D., will participate in the Mizuho Neuroscience Summit being held May 20 – 21 at the Boston Harbor Hotel.
  • Drs.
  • Berman and Swaminathan will also be available for one-on-one meetings throughout the conference.
  • More information on the Mizuho Neuroscience Summit can be found at the link below: https://www.mizuhogroup.com/americas/events/2024/mizuho-neuroscience-sum...

Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit

Retrieved on: 
torsdag, april 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, COYA, Combination, Drug development, D.O, FAPA, Hurdling, Treatment, ALS, Therapy, Medical device

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA will participate in the 3rd Annual ALS Drug Development Summit being held May 21 – 23 at the Hyatt Regency in Boston.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA will participate in the 3rd Annual ALS Drug Development Summit being held May 21 – 23 at the Hyatt Regency in Boston.
  • On May 21 from 11am – 1pm ET, Dr. Grossman will co-lead a workshop discussion titled, “Navigating the Hurdles of a Combination Therapy Approach & the Need to Demonstrate Efficacy on Top of Existing ALS Treatments” in Workshop B.
  • On May 23 at 1:10pm ET, Dr. Grossman will give a presentation titled, “COYA 302: A Dual Mechanism Biologic Immunotherapy in the Treatment of ALS by Treg Activity to Reduce Inflammation.”
    For more information on the 3rd Annual ALS Drug Development Summit and to register, please visit:

Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Retrieved on: 
måndag, april 8, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diagnosis, Pharmacology, Conference, Survival, Coya, Associate, Patient, Biomarker, COYA, Medulla oblongata, Death, Society, Doctor of Philosophy, Therapy, Poster, FDA

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April 26, 2024.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April 26, 2024.
  • The title of the poster is 4-hydroxynonenal (4-HNE) as a Biomarker in ALS.
  • During the Johnson Center Symposium, Dr. Appel will present data correlating 4-HNE levels to bulbar and limb onset ALS.
  • Coya plans to discuss the validation of 4-HNE as a new potential biomarker for ALS and the potential inclusion of 4-HNE as a biomarker in the planned Ph.

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

Retrieved on: 
tisdag, mars 19, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Research, Pharmacology, LD, Survival, Serum, ALS, Science, PD, Houston Methodist Hospital, Patient, Regulatory affairs, Granulocyte-macrophage colony-stimulating factor, FD, GM-CSF, Nebraska Medicine, COYA, University, IPO, Senior, Society, IND, Commerce, Viral disease, Therapy, Frontotemporal dementia, FDA, FTD, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023.
  • COYA 302 is Coya’s combination of its proprietary LD IL-2 formulation with the immunomodulatory drug CTLA4-Ig.
  • “We believe that we have under-promised and over-delivered in executing on numerous deliverables in 2023 that have brought value to Coya,” commented Howard Berman, Ph.D., Chief Executive Officer of Coya.
  • Net loss was $8.0 million for the year ended December 31, 2023, compared to net loss of $12.2 million for the year ended December 31, 2022.

Coya Therapeutics to Participate in BTIG Fireside Discussion

Retrieved on: 
tisdag, mars 12, 2024
Biotechnology, Pharmaceutical, Health, Neurology, COYA, Survival, Therapy, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board and Chief Medical Officer Dr. Fred Grossman will participate in a fireside discussion with BTIG analyst Tom Shrader on Wednesday, March 13, 2024, at 12pm ET.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board and Chief Medical Officer Dr. Fred Grossman will participate in a fireside discussion with BTIG analyst Tom Shrader on Wednesday, March 13, 2024, at 12pm ET.
  • Topics to be discussed include the role of regulatory T cells in treating neurodegenerative diseases, the biomarker (4-HNE) ALS survival data presented today by Dr. Stanley Appel, and Coya’s regulatory pathway for COYA 302, its lead drug candidate that is being explored in Amyotrophic Lateral Sclerosis (ALS), Parkinson’s disease, Frontotemporal disease, and Alzheimer’s disease.
  • Investors interested in attending this event should contact their respective BTIG representative to be granted access.